GlassScriptPhysician profile
Rusina Karia
NPI 1508531567
$385.80
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.44 · 2022: $15.32 · 2023: $280 · 2024: $78.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $126.14 | 2023 | Tukysa |
| Ucb, INC. | $31.35 | 2024 | Cimzia |
| Incyte Corporation | $30.35 | 2023 | Pemazyre, Monjuvi, Jakafi |
| Janssen Pharmaceuticals, INC | $27.76 | 2021-2022 | |
| Abbvie INC. | $27.25 | 2023 | |
| Astellas Pharma US INC | $26.54 | 2023 | Xospata |
| Merck Sharp & Dohme LLC | $20.64 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Csl Behring | $18.95 | 2023 | Haegarda |
| Azurity Pharmaceuticals, INC. | $17.00 | 2024 | Edarbyclor |
| E.R. Squibb & Sons, L.L.C. | $16.32 | 2024 | Eliquis |
| Pacira Pharmaceuticals Incorporated | $15.16 | 2023 | Zilretta, Iovera, Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $14.79 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.55 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rusina Karia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.